EGFR and neoplasm: This open-label, phase 1 study provided novel findings regarding the safety and tumor response of DS-1205c, a kinase inhibitor that selectively targets AXL, in combination with osimertinib in 13 patients with metastatic or unresectable EGFR-mutant NSCLC.